Skip to content
★ Sign in to follow
JF

J Ford

GlaxoSmithKline plc
Total declarations
111
Company
1
▲ Purchases (2 ops.)
€337k
▼ Sales (3 ops.)
€433k

Latest filing published 01 Mar 2022 for GlaxoSmithKline plc, €2,759.

Filing timeline

BuySale
J Ford

Insider track record

Disclosed buys
2
Disclosed sells
3
Signal history

Closed purchases

Market purchases
2

Not enough history yet: 0 closed purchases, at least 2 are needed.

Purchases by company

J Ford: trading record in brief

J Ford appears in our data through filings on GlaxoSmithKline plc shares, published by RNS (LSE). The record holds 111 filings, for trades running from 6 September 2018 to 24 February 2022.

In open-market terms, that means 2 purchases worth €337k on one side and 3 sales worth €433k on the other. The amount is not disclosed for 1 filing. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Outside the open market, there are 106 share grants.

The newest entry dates from 1 March 2022: a share grant of €2,759, in GlaxoSmithKline plc. The latest purchase dates back some time: it was published 2,092 days ago, on 15 February 2021. Between a trade and the moment it shows up on RNS (LSE), the median delay is 2 days. Under the UK Market Abuse Regulation, managers have three business days to notify their trades. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. Source: insider filings from RNS (LSE). Past trades are no guide to future returns.

Companies and markets linked to J Ford

Open company profiles for insider transactions, fundamentals and analyst consensus when available.

Declarations111 total
  • ◆
    SVP and Group General Counsel, Legal and ComplianceExecutivesGlaxoSmithKline plc
    3,120 USD0FCA-NSM
    75.736 shares@ US$41.1901New York Stock Exchange (XNYS)ISIN US37733W1053FCA-NSM:4287165-2
  • ◆
    SVP and General CounselExecutivesGlaxoSmithKline plc
    0FCA-NSM
    46,446 shares0N/AISIN US37733W1053FCA-NSM:4277167-7
  • ◆
    SVP and General CounselExecutivesGlaxoSmithKline plc
    946,121 USD0FCA-NSM
    21,830 shares@ US$43.3404New York Stock Exchange (XNYS)ISIN US37733W1053FCA-NSM:4277167-8
  • ◆
    SVP and General CounselExecutivesGlaxoSmithKline plc
    0FCA-NSM
    3,725 shares0N/AISIN US37733W1053FCA-NSM:4275770-6
  • ◆
    SVP and General CounselExecutivesGlaxoSmithKline plc
    0FCA-NSM
    1,974 sharesN/AISIN US37733W1053FCA-NSM:4275770-7
  • ◆
    SVP and General CounselExecutivesGlaxoSmithKline plc
    0FCA-NSM
    157,331 sharesN/AISIN GB0009252882FCA-NSM:4275767-4
  • ◆
    SVP and General CounselExecutivesGlaxoSmithKline plc
    0FCA-NSM
    13,998 sharesN/AISIN GB0009252882FCA-NSM:4275763-5
  • ◆
    SVP and General CounselExecutivesGlaxoSmithKline plc
    260 GBP0FCA-NSM
    16 shares@ £16.27London Stock Exchange (XLON)ISIN GB0009252882FCA-NSM:4269726-3
  • ◆
    SVP & General CounselExecutivesGlaxoSmithKline plc
    4,895 USD0FCA-NSM
    105.881 shares@ US$46.2266New York Stock Exchange (XNYS)ISIN US37733W1053FCA-NSM:4246765-1
  • ◆
    SVP & General CounselExecutivesGlaxoSmithKline plc
    0FCA-NSM
    0 shares@ £0.00London Stock Exchange (XLON)ISIN GB0009252882FCA-NSM:4245332-3
  • ◆
    Senior Vice President and General CounselExecutivesGlaxoSmithKline plc
    3,605 GBP0FCA-NSM
    221 shares@ £16.312London Stock Exchange (XLON)ISIN GB0009252882FCA-NSM:4245272-5
  • ◆
    Senior Vice President and General CounselExecutivesGlaxoSmithKline plc
    1,847 USD0FCA-NSM
    41 shares@ US$45.06New York Stock Exchange (XNYS)ISIN US37733W1053FCA-NSM:4245272-6
  • ◆
    SVP & General CounselExecutivesGlaxoSmithKline plc
    65 GBP0FCA-NSM
    4 shares@ £16.3525London Stock Exchange (XLON)ISIN GB0009252882FCA-NSM:4240643-3
  • ◆
    SVP and General CounselExecutivesGlaxoSmithKline plc
    229 GBP0FCA-NSM
    14 shares@ £16.3779London Stock Exchange (XLON)ISIN GB0009252882FCA-NSM:4239325-3
  • ◆
    SVP and General CounselExecutivesGlaxoSmithKline plc
    256 GBP0FCA-NSM
    16 shares@ £16.0119London Stock Exchange (XLON)ISIN GB0009252882FCA-NSM:4209773-3
  • ◆
    SVP & General CounselExecutivesGlaxoSmithKline plc
    2,606 USD0FCA-NSM
    62.798 shares@ US$41.50New York Stock Exchange (XNYS)ISIN US37733W1053FCA-NSM:4188482-2
  • ◆
    SVP and General CounselExecutivesGlaxoSmithKline plc
    250 GBP0FCA-NSM
    16 shares@ £15.6294London Stock Exchange (XLON)ISIN GB0009252882FCA-NSM:4176605-3
  • ◆
    SVP & General CounselExecutivesGlaxoSmithKline plc
    4,837 USD0FCA-NSM
    124.958 shares@ US$38.7117New York Stock Exchange (XNYS)ISIN US37733W1053FCA-NSM:4146115-1
  • ◆
    Senior Vice President and General CounselExecutivesGlaxoSmithKline plc
    3,544 GBP0FCA-NSM
    253 shares@ £14.008London Stock Exchange (XLON)ISIN GB0009252882FCA-NSM:4144793-5
  • ◆
    Senior Vice President and General CounselExecutivesGlaxoSmithKline plc
    1,817 USD0FCA-NSM
    47 shares@ US$38.66New York Stock Exchange (XNYS)ISIN US37733W1053FCA-NSM:4144793-6
  • ◆
    SVP & General CounselExecutivesGlaxoSmithKline plc
    0FCA-NSM
    0 shares@ £0.00London Stock Exchange (XLON)ISIN GB0009252882FCA-NSM:4144789-3
  • ◆
    SVP and General CounselExecutivesGlaxoSmithKline plc
    252 GBP0FCA-NSM
    18 shares@ £13.9739London Stock Exchange (XLON)ISIN GB0009252882FCA-NSM:4141728-3
  • ◆
    SVP & General CounselExecutivesGlaxoSmithKline plc
    56 GBP0FCA-NSM
    4 shares@ £13.94London Stock Exchange (XLON)ISIN GB0009252882FCA-NSM:4141620-3
  • ◆
    SVP and General CounselExecutivesGlaxoSmithKline plc
    259 GBP0FCA-NSM
    18 shares@ £14.3928London Stock Exchange (XLON)ISIN GB0009252882FCA-NSM:4108557-3
  • ◆
    SVP & General CounselExecutivesGlaxoSmithKline plc
    2,607 USD0FCA-NSM
    62.356 shares@ US$41.8099New York Stock Exchange (XNYS)ISIN US37733W1053FCA-NSM:4087465-2

25 of 111 declarations